Intellipharmaceutics International (OTCMKTS:IPCIF) vs. Neoleukin Therapeutics (NASDAQ:NLTX) Head-To-Head Contrast

Earnings and Valuation

This table compares Intellipharmaceutics International and Neoleukin Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellipharmaceutics International	$660,000.00	0.00	-$2.89 million	($0.16)	N/A
Neoleukin Therapeutics	N/A	N/A	-$57.56 million	($3.11)	-5.68

Intellipharmaceutics International has higher revenue and earnings than Neoleukin Therapeutics. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Intellipharmaceutics International, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

52.4% of Neoleukin Therapeutics shares are held by institutional investors. 1.8% of Intellipharmaceutics International shares are held by company insiders. Comparatively, 1.6% of Neoleukin Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Intellipharmaceutics International has a beta of 1.53, meaning that its share price is 53% more volatile than the S&P 500. Comparatively, Neoleukin Therapeutics has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500.

Profitability

This table compares Intellipharmaceutics International and Neoleukin Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Intellipharmaceutics International	N/A	N/A	N/A
Neoleukin Therapeutics	N/A	-37.22%	-30.91%

Summary

Intellipharmaceutics International beats Neoleukin Therapeutics on 8 of the 9 factors compared between the two stocks.

About Intellipharmaceutics International

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. In addition, it provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. Further, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. Intellipharmaceutics International Inc. was founded in 1998 and is based in Toronto, Canada.

About Neoleukin Therapeutics

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.